Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vera Therapeutics

< Previous 1 2 Next >
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
Tickers VERA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.